Forty Seven FTSV and Ono Pharmaceutical have inked an exclusive license agreement for the development, manufacture and commercialization of 5F9, Forty Seven’s monoclonal antibody against CD47.
The agreement includes all therapeutic uses of 5F9 as a monotherapy or combination agent in Japan, South Korea, Taiwan and the ASEAN countries.
Forty Seven is a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer. The company will retain all rights to 5F9 in the rest of the world including the US, Europe, and China.
Forty Seven shares are trading down 0.8% at $10.17 Thursday morning. The stock has a 52-week high of $23.83 and a 52-week low of $9.90.
Related Links:
Ohr Pharmaceutical Merger With Neubase Therapeutics Approved By Shareholders
Can-Fite BioPharma Appeals Lawsuit Against Venture Capital Firm
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
